Compare BioNTech SE - ADR (BNTX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Procter & Gamble Co — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Procter & Gamble Co trades at $146.15 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 14.9× BioNTech SE - ADR's market cap, and Procter & Gamble Co pays a 2.92% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PG | |
|---|---|---|
Market Cap | $22.86B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $167.18 |
52-Week Low | $83.89 | $138.10 |
Enterprise Value | $6.53B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Procter & Gamble (PG) trades at $148.37, up 0.9% with a neutral technical outlook. The company maintains strong fundamentals with $84.28B revenue and 19.16% net income margin, consistently beating earnings estimates. Recent dividend declaration of $1.09 and WNBA partnership highlight stable returns and brand expansion. Analyst consensus is bullish with 53.85% buy ratings and $161.71 price target, though premium valuation metrics suggest cautious optimism.
PG offers steady growth with reliable dividends but faces margin pressure from rising costs. The stock's premium valuation requires sustained earnings growth to justify upside. Near-term resistance at $150 presents a key level to watch, while support at $145 provides downside protection. Institutional activity remains mixed amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
